The University of Chicago Header Logo

Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?

Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? J Clin Oncol. 2005 Nov 01; 23(31):8124-5; author reply 8125-6.

View in: PubMed